Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol
暂无分享,去创建一个
Kevin W. Gaido | Janet C. Gould | Linda S. Leonard | Susan C. Maness | Brandee L. Wagner | S. Safe | T. Zacharewski | K. Gaido | S. Maness | D. McDonnell | L. Leonard | J. Gould | B. Wagner | Kevin Conner | L. S. Leonard
[1] B. Katzenellenbogen,et al. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Wakeling,et al. A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.
[3] L. E. Romine,et al. Effects of wild type and mutant estrogen receptors on DNA flexibility, DNA bending, and transcription activation. , 1996, Molecular endocrinology.
[4] J. McLachlan,et al. A yeast estrogen screen for examining the relative exposure of cells to natural and xenoestrogens. , 1996, Environmental health perspectives.
[5] The developmental toxicity of bisphenol A in rats and mice. , 1987, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[6] K. Korach,et al. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. , 1993, Molecular endocrinology.
[7] B. Howard,et al. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.
[8] N. Koszewski,et al. Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. , 1993, Biochemistry.
[9] Daniel Metzger,et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.
[10] L. Gianaroli,et al. Molecular and cellular endocrinology , 1992, Molecular and Cellular Endocrinology.
[11] R. Bigsby,et al. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. , 1997, Endocrinology.
[12] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[13] J. Gustafsson,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.
[14] J. Pike,et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.
[15] N. Olea,et al. Xenoestrogens released from lacquer coatings in food cans. , 1995, Environmental health perspectives.
[16] D G Hoel,et al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. , 1993, Environmental health perspectives.
[17] K. Korach,et al. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.
[18] N. Webster,et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.
[19] Division on Earth. Guide for the Care and Use of Laboratory Animals , 1996 .
[20] B. Katzenellenbogen,et al. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.
[21] C Sonnenschein,et al. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. , 1995, Environmental health perspectives.
[22] S. Koike,et al. Molecular cloning and characterization of rat estrogen receptor cDNA. , 1987, Nucleic acids research.
[23] C. Portier,et al. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. , 1997, Toxicology and applied pharmacology.
[24] D. Picard,et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.
[25] D. Williams,et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.
[26] F. Olea-Serrano,et al. Estrogenicity of resin-based composites and sealants used in dentistry. , 1996, Environmental health perspectives.
[27] R M Sharpe,et al. Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. , 1995, Environmental health perspectives.
[28] P. Chambon,et al. Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.
[29] B. Katzenellenbogen,et al. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. , 1982, Journal of steroid biochemistry.
[30] V. Jordan,et al. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. , 1987, Cancer research.
[31] B. O’Malley,et al. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Willson,et al. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.
[33] M. Tzukerman,et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.
[34] Jean-Paul Renaud,et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.
[35] K. Korach,et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] N. Olea,et al. The E-screen assay: a comparison of different MCF7 cell stocks. , 1995, Environmental health perspectives.
[37] D. Feldman,et al. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. , 1993, Endocrinology.
[38] E. Kalkhoven,et al. Negative Interaction between the RelA(p65) Subunit of NF-B and the Progesterone Receptor (*) , 1996, The Journal of Biological Chemistry.
[39] G. W. Davis,et al. Evaluation of a New Reproductive Toxicology Protocol Using Diethylstilbestrol (DES) as a Positive Control Compound , 1985 .
[40] A. Soto,et al. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. , 1993, Environmental health perspectives.
[41] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[42] A. Philips,et al. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. , 1993, Endocrinology.
[43] Elisabeth Scheer,et al. Distinct classes of transcriptional activating domains function by different mechanisms , 1990, Cell.
[44] P. Chambon,et al. Functional domains of the human estrogen receptor , 1987, Cell.